

# EHC Workshop on New Technologies in Haemophilia Care



22-24 November 2019

Athens, Greece

DRAFT PROGRAMME

22 Nov	23 Nov	24 Nov
	<p>09.00 – 09.05 Welcome and introduction to the workshop</p> <p><u>Licensed therapies</u></p> <p>09.05 – 09.35 Hemlibra: Overview of real-world evidence in inhibitor patients – <i>What have we achieved and what have we lost?</i></p> <p>09.35 – 10.05 Hemlibra: Overview of real-world evidence in non-inhibitor patients</p> <p>10.05 – 10.25 Q&amp;A</p> <p>10.25 – 10.45 <i>Coffee break</i></p> <p>10.45 – 11.15 Extended half-life: Real-world evidence for efficacy (trough)</p> <p>11.15 – 11.45 Extended half-life: Safety of PEG</p> <p>11.45 – 12.00 Q&amp;A</p> <p>12.00 – 12.20 <i>Coffee break (coffee only)</i></p> <p>12.20 – 12.50 Update on Vonvendi: Indications for use how use rVWF in surgery</p> <p>12.50 – 13.00 Q&amp;A</p>	<p>09.00 – 09.05 Welcome and introduction</p> <p><u>Gene Therapy</u></p> <p>09.05 – 09.35 Current state of play with clinical trials in gene therapy</p> <p>09.35 – 10.05 Re-treatment with vector for gene therapy</p> <p>10.05 – 10.25 Q&amp;A</p> <p>10.25 – 10.40 <i>Coffee break</i></p> <p>10.40 – 11.10 Unanswered questions with adeno-associated virus</p> <p>11.10 – 11.50 Regulatory &amp; Patient Perspectives: Future ethical considerations of enrolling children in gene therapy</p> <p>11.50 – 12.20 How will we pay for gene therapy in Europe</p> <p>12.20 – 12.35 <i>Coffee Break (coffee only)</i></p> <p><u>Panel discussions</u></p> <p>12.35 – 13.20 Which patients should be prioritised for gene therapy – Views from clinicians, payers and patients</p> <p>13.20 – 13.30 Conclusions and evaluations</p>
	<p>13.00-14.00 <i>Lunch</i></p>	<p>13.30 - 14.30 <i>Lunch and departures</i></p>

*This workshop was made possible thanks to the sponsorship of BioMarin*

<p>16.00-18.00 – Registration</p>	<p><b>14.00 – 14.30 Novel therapies: Access and affordability in Europe</b></p> <p><b>14.30 – 15.00 Novel therapies: Safety and ongoing post-marketing trials</b></p> <p><b>15.00 – 15.20 Q&amp;A</b></p> <p>15.20 – 15.40 Coffee Break (coffee only)</p> <p><b><u>Therapies in Clinical Trials</u></b></p> <p><b>15.40 – 16.10 Update on SerpinSC</b></p> <p><b>16.10 – 16.40 Update on anti-TFPI</b></p> <p>16.40 – 17.00 Q&amp;A</p> <p>17.00 – 17.20 Coffee Break</p> <p><b><u>Panel discussion</u></b></p> <p><b>17.20 – 18.00 With standard half-life, extended half-life, Hemlibra and gene therapy available or on the way: How will we chose which therapies to choose for which patients and how will we compare affordability?</b></p>	
<p>19.00-21.00 – Dinner</p>	<p>19.00 – 20.00 <i>Social activity</i></p> <p>20.00-22.00 – <i>Workshop Dinner</i></p>	

*This workshop was made possible thanks to the sponsorship of BioMarin*